TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Clinical trials for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM) trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for rare heart disease in Long-Term safety trial
Disease control ENROLLING_BY_INVITATIONThis study looks at the long-term safety of a drug called eplontersen in people with a heart condition known as ATTR-CM, where abnormal proteins build up in the heart. About 1400 adults who completed earlier studies or have this diagnosis will receive the drug and be monitored fo…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:35 UTC
-
Heart scan sub-study tests Drug's effect on sticky protein buildup
Disease control OngoingThis study is for people with a heart condition called ATTR-CM, where a protein called transthyretin builds up in the heart. It tests whether the drug eplontersen can reduce that buildup compared to a placebo. About 150 participants will have special heart scans at 140 weeks to s…
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 11:32 UTC
-
Heart MRI study aims to see how amyloid builds up over time
Knowledge-focused OngoingThis study uses MRI scans to measure amyloid protein buildup in the heart of up to 150 people with a heart condition called ATTR-CM. Participants are already in a larger treatment study. The goal is to see how the amount of amyloid changes over time, not to test a new treatment. …
Matched conditions: TRANSTHYRETIN-MEDIATED AMYLOID CARDIOMYOPATHY (ATTR-CM)
Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated May 17, 2026 11:37 UTC